Detailed Mechanism Funding and Narrative

Years of mechanism: 2015 2016 2017 2018

Details for Mechanism ID: 18005
Country/Region: Malawi
Year: 2018
Main Partner: KNCV Tuberculosis Foundation
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USAID
Total Funding: $1,640,000 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $0
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $1,485,000
Care: Pediatric Care and Support (PDCS) $0
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $155,000
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $0
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $0
Treatment: Pediatric Treatment (PDTX) $0
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 114
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 793
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 114
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 1,249
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 2,268
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 182
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 1,279
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 182
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 2,009
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period. 2019 3,650
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 3,681
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 183
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 1,289
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 183
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 2,026
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 136,895
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 6,843
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 6,843
TX_TB_den Denominator: By Aggregated Age/Sex: 15+, Female 2019 47,915
TX_TB_den Denominator: By Aggregated Age/Sex: 15+, Male 2019 75,294
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 82,133
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 54,762
TX_TB_den Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 136,895
TX_TB_den Life-long ART, Already, TB Screen - Negative, Positive 2019 121,841
TX_TB_den Life-long ART, Already, TB Screen - Positive, Positive 2019 1,366
TX_TB_den Life-long ART, New, TB Screen - Negative, Positive 2019 13,552
TX_TB_den Life-long ART, New, TB Screen - Positive, Positive 2019 136
Mechanism Allocation by Budget Code for Selected Year
5.2%5.9%6.5%7.2%7.8%8.5%9.2%9.8%10.5%11.1%0024681012141618HBHCHKIDHVTBPDCSHLABHVSIOHSSCIRCHMBLHMINHVABHVCTHVOPIDUPMTCTHTXDHTXSPDTX
Cross Cutting Budget Categories and Known Amounts Total: $203,000
Renovation $155,000
Motor Vehicles: Leased $48,000